CNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Context Therapeutics Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$0.24−0.01 (-2.30%)

Close on Oct 19, 2026

Market cap: $22.69M
P/E (TTM): –
Dividend yield: –

Context Therapeutics Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Cash & Equivalents	66	94	14	35	50	0.34	0.23
Cash & Short-Term Investments	66	94	14	35	50	0.34	0.23
Prepaid Expenses & Other	2.36	3.47	1.60	2.36	1.62	0.01	–
Total Current Assets	68	98	16	38	51	0.30	–
Property, Plant & Equipment	0.03	0.01	0.02	0.03	0	–	–
Operating Lease Right-of-Use Assets	0.11	0.22	0	0.05	0	–	–
Other Long-Term Assets	–	–	0	0.03	0	–	–
Total Assets	68	98	16	38	51	0.47	–
Accounts Payable	2.53	1.45	2.38	0.94	1.83	2.71	–
Accrued Expenses	5.38	1.19	1.81	2.22	1.21	0.96	–
Current Portion of Leases	0.11	0.11	0	0.06	0	–	–
Total Current Liabilities	8.02	2.75	4.19	3.21	3.03	9.55	–
Long-Term Debt	–	–	–	–	0	0.07	–
Long-Term Leases	0	0.11	0	–	0	–	–
Operating Lease Liabilities	0.10	0.20	0	0.06	0	–	–
Total Liabilities	8.02	2.86	4.19	3.21	3.03	9.62	–
Total Debt	–	–	–	–	0	0.07	–
Preferred Stock	0	0	0	0	0	0	–
Common Stock	0.09	0.09	0.02	0.02	0.02	0.00	–
Additional Paid-In Capital	191	190	80	79	78	1.88	–
Retained Earnings	-131	-95	-68	-44	-29	-19	–
Shareholders' Equity	60	95	12	35	48	-17	-24
Total Equity	60	95	12	35	48	-17	-24
Total Liabilities & Equity	68	98	16	38	51	0.47	–
Shares Outstanding(shares)	92	90	16	16	16	0.33	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -46.4%

Financial strength

Current ratio: 5.81
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 545.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.59
Dividend yield: –